An interventional study of Pulmonary artery catheter in Heart Failure With Reduced Ejection Fraction and Cardiogenic Shock, sponsored by Min-Seok Kim. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-01-05.
Sponsored by Min-Seok Kim · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Shock, Cardiogenic with a site in Korea, Republic of — 8 open to participants now, 8 under way, none of them phase 3. Shock, Cardiogenic · Korea, Republic of.
Among the 13 studies in Shock, Cardiogenic with a site in Korea, Republic of, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 8 with no phase, and was the 9th registered.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →8 of the 13 studies in Shock, Cardiogenic with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Min-Seok Kim · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 80 across 133 interventional studies indexed under Shock, Cardiogenic.
Median enrollment 280 across the 10 interventional studies, 1,000 across the 3 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 6 most frequent:
Min-Seok Kim is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Min-Seok Kim has 2 studies filed under Shock, Cardiogenic — fewer than ten, so there is no comparison to draw.
2 of the studies in Shock, Cardiogenic with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05698628Min-Seok KimDistal Perfusion Timing, Early or Conservative, to Prevent Limb Ischemia During Peripheral VA-ECMO | 2027-02-28 |
| NCT06078436Min-Seok KimPulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Due to HFrEF | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Shock, Cardiogenic with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to compare the impact of hemodynamic monitoring using pulmonary artery catheter (PAC) on survival and inotropic agent reduction in patients with cardiogenic shock caused by heart failure with reduced ejection fraction (HFrEF). The investigators also intend to compare the difference in long-term survival rates among patients who have recovered from cardiogenic shock due to HFrEF, based on the timing of initiation of beta-blocker treatment.
Cardiogenic shock is one of the most common causes of shock patients admitted to the Cardiac Intensive Care Unit (CICU). Despite advances in treatment, the mortality rate of cardiogenic shock remains high, up to 50%, and improving survival is crucial through the use of inotropic agents, vasopressors, or mechanical circulatory support devices to improve hemodynamic parameters. Previous meta-analyses of retrospective studies have shown the usefulness of pulmonary artery catheter monitoring, especially in patients with cardiogenic shock due to heart failure. However, there is a lack of prospective studies regarding specific monitoring indicators and treatment goals. This study aims to compare the impact of hemodynamic monitoring through pulmonary artery catheter on survival and inotropic agent reduction in patients with cardiogenic shock caused by heart failure with reduced ejection fraction.
In the PAC non-monitoring group, various assessments such as physical examination, echocardiographic findings, serum lactate levels, chest x-ray, and laboratory test results are utilized. If there are signs of volume overload, diuretics or hemodialysis may be applied to achieve for volume reduction. The dosage of diuretics and the timing of hemodialysis are at the discretion of the attending physician. The target of a mean arterial pressure (MAP) is 65mmHg or higher. If the MAP falls below 65mmHg, increasing vasopressor or inotropes should be considered. If the MAP target is not achieved with medical therapy or if serum lactate levels increase by 3 mmol/L or more compared to the lowest value within 24 hours, mechanical circulatory support (MCS) is considered. The specific dosage of vasopressors/inotropes and the timing of MCS application are at the dscretion of the attending physician.
The PAC monitoring group, in addition to those used in the PAC non-monitoring group, treats patients using indicators measured by PAC. The targets include a right atrial pressure (RAP) or central venous pressure (CVP) of 8mmHg or lower and pulmonary capillary wedge pressure (PCWP) of 15mmHg or lower. Whan RAP or CVP exceeds 8mmHg, or PCWP exceeds 15mmHg, employing diuretics or hemodialysis should be considered for volume reduction. The dosage of diuretics and the timing of hemodialysis are at the discretion of the attending physician. The target of a mean arterial pressure (MAP) is 65mmHg or higher. If the MAP falls below 65mmHg, increasing vasopressor or inotropes should be considered. If the MAP target is not achieved with medical therapy or if serum lactate levels increase by 3 mmol/L or more compared to the lowest value within 24 hours, mechanical circulatory support (MCS) is considered. The specific dosage of vasopressors/inotropes and the timing of MCS application are at the dscretion of the attending physician.
Additionally, the beta-blocker Carvedilol is known to reduce mortality and readmission rates in heart failure patients based on large-scale clinical trials and is widely prescribed as a standard treatment. However, the evidence for the appropriate timing of Carvedilol initiation and objective indicators of hemodynamic stability beyond the point of discharge is currently insufficient, relying solely on the clinical judgment and experience of the treating physician. Through subgroup analysis, the investigators intend to compare the difference in long-term survival rates among patients who have recovered from cardiogenic shock due to heart failure with reduced ejection fraction, based on the timing of iniation of beta-blocker treatment. The early administration of Carvedilol is defined as initiating treatment within 24 to 48 hours after discontinuing vasopressor/inotropic agents or mechanical circulatory support in stable condition following cardiogenic shock. The conservative administration of Carvedilol is defined as initiating treatment at least 48 hours after discontinuing vasopressors/inotropic agents or mechanical circulatory support in stable condition following cardiogenic shock.
Also, lung B-line will be measure along with PAC measured hemodynamic parameters using lung ultrasound at eight regions of the thorax in patients with PAC monitoring. Number of B-line in a total and each region, positive region which is defined as having three or more number of B-line will be recorded. Acquired images will be adjudicated by two investigators who are blinded to the clinical information of the subject.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Within 8 hours of random allocation, a pulmonary artery catheter will be inserted to monitor hemodynamic parameters.
Device: Pulmonary artery catheter
After random allocation, a pulmonary artery catheter will not be inserted during cardiogenic shock management.
Device: Pulmonary artery catheter
Pulmonary artery catheter monitoring or not
Also known as: Swan-Ganz catheter
30-day all-cause mortality
All-cause mortality
Time frame: From date of randomization until the date of death from any cause, assessed up to 30 days
All-cause mortality
All-cause of death
Time frame: From date of randomization until the date of death from any cause, assessed up to 3 months
Cardiovascular mortality
Cardiovascular death
Time frame: From date of randomization until the date of death from any cause, assessed up to 3 months
Timing of discontinuation of inotropic or vasopressor agents
Days from randomization to discontinuation of inotropes/vasopressor
Time frame: From date of randomization until the date of discharge or assessed up to 90 days
The rate of Carvedilol intake on the 3 months
The rate of Carvedilol intake
Time frame: 3 months from date of randomization
The target-dose achievement rate of Carvedilol on the 3 months
Target dose : 50mg/day
Time frame: 3 months from date of randomization
3-month follow-up echocardiography parameters
LVEF(left ventricular ejection fraction)
Time frame: 3 months from date of randomization
Complications related with pulmonary artery catheter
Any complications related with pulmonary artery catheter
Time frame: During hospitalization period, up to 30 days
Hospitalization due to heart failure
Unplanned hospitalization due to heart failure
Time frame: 3 months from date of randomization
The composite outcome of cardoivascular death and heart failure hospitalization
The composite outcome of cardiovascular death and hospitalization due to heart failure
Time frame: 3 months from date of randomization
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2024; primary completion for Sep 2027, 44 months later.
Of 48 non-industry interventional studies with no phase under Shock, Cardiogenic, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 44 months is above that.
Counting every sponsor, half of 52 studies reached it within 39 months; a quarter within 24 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Min-Seok Kim